GRAIL, Inc.GRALEarnings & Financial Report
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
GRAL Q3 2025 Key Financial Metrics
Revenue
$36.2M
Gross Profit
N/A
Operating Profit
$-125.3M
Net Profit
$-89.0M
Gross Margin
N/A
Operating Margin
-346.2%
Net Margin
-245.8%
YoY Growth
26.3%
EPS
$-2.46
Financial Flow
GRAIL, Inc. Q3 2025 Financial Summary
GRAIL, Inc. reported revenue of $36.2M for Q3 2025, with a net profit of $-89.0M (-245.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $36.2M |
|---|---|
| Net Profit | $-89.0M |
| Gross Margin | N/A |
| Operating Margin | -346.2% |
| Report Period | Q3 2025 |
GRAIL, Inc. Annual Revenue by Year
GRAIL, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $125.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $125.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.7M | $26.7M | $32.0M | $28.7M | $38.3M | $31.8M | $35.5M | $36.2M |
| YoY Growth | N/A | N/A | 42.6% | N/A | 84.6% | 19.1% | 11.2% | 26.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.91B | N/A | $3.27B | $3.12B | $2.98B | $2.85B | $2.70B | $2.60B |
| Liabilities | $267.6M | N/A | $574.5M | $530.3M | $479.9M | $433.9M | $387.9M | $361.1M |
| Equity | N/A | N/A | $2.70B | $2.59B | $2.50B | $2.41B | $2.31B | $2.24B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-207.3M | $-171.8M | $-104.6M | $-95.0M | $-77.0M | $-63.2M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
TXG
10x Genomics, Inc.
Revenue
$166.0M
Net Profit
$-16.3M
DFTX
Mind Medicine (MindMed) Inc.
Revenue
$906.0K
Net Profit
$-23.9M
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Revenue
$38.4M
Net Profit
$-38.0M
ASMB
ASSEMBLY BIOSCIENCES, INC.
Revenue
$10.8M
Net Profit
$-9.2M
DTIL
PRECISION BIOSCIENCES INC
Revenue
$13.0K
Net Profit
$-21.8M